» Articles » PMID: 24395240

Identification of a Key Lysine Residue in Heat Shock Protein 90 Required for Azole and Echinocandin Resistance in Aspergillus Fumigatus

Overview
Specialty Pharmacology
Date 2014 Jan 8
PMID 24395240
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Heat shock protein 90 (Hsp90) is an essential chaperone involved in the fungal stress response that can be harnessed as a novel antifungal target for the treatment of invasive aspergillosis. We previously showed that genetic repression of Hsp90 reduced Aspergillus fumigatus virulence and potentiated the effect of the echinocandin caspofungin. In this study, we sought to identify sites of posttranslational modifications (phosphorylation or acetylation) that are important for Hsp90 function in A. fumigatus. Phosphopeptide enrichment and tandem mass spectrometry revealed phosphorylation of three residues in Hsp90 (S49, S288, and T681), but their mutation did not compromise Hsp90 function. Acetylation of lysine residues of Hsp90 was recovered after treatment with deacetylase inhibitors, and acetylation-mimetic mutations (K27A and K271A) resulted in reduced virulence in a murine model of invasive aspergillosis, supporting their role in Hsp90 function. A single deletion of lysine K27 or an acetylation-mimetic mutation (K27A) resulted in increased susceptibility to voriconazole and caspofungin. This effect was attenuated following a deacetylation-mimetic mutation (K27R), suggesting that this site is crucial and should be deacetylated for proper Hsp90 function in antifungal resistance pathways. In contrast to previous reports in Candida albicans, the lysine deacetylase inhibitor trichostatin A (TSA) was active alone against A. fumigatus and potentiated the effect of caspofungin against both the wild type and an echinocandin-resistant strain. Our results indicate that the Hsp90 K27 residue is required for azole and echinocandin resistance in A. fumigatus and that deacetylase inhibition may represent an adjunctive anti-Aspergillus strategy.

Citing Articles

Sirtulin-Ypk1 regulation axis governs the TOR signaling pathway and fungal pathogenicity in .

Chai Z, Li Y, Zhang J, Ding C, Tong X, Zhang Z Microbiol Spectr. 2024; :e0003824.

PMID: 38912819 PMC: 11302014. DOI: 10.1128/spectrum.00038-24.


Molecular mechanisms governing antifungal drug resistance.

Lee Y, Robbins N, Cowen L NPJ Antimicrob Resist. 2024; 1(1):5.

PMID: 38686214 PMC: 11057204. DOI: 10.1038/s44259-023-00007-2.


Potential Antifungal Targets for sp. from the Calcineurin and Heat Shock Protein Pathways.

Ancuceanu R, Hovanet M, Cojocaru-Toma M, Anghel A, Dinu M Int J Mol Sci. 2022; 23(20).

PMID: 36293395 PMC: 9603945. DOI: 10.3390/ijms232012543.


Potential antifungal targets based on histones post-translational modifications against invasive aspergillosis.

Li Y, Song Z, Wang E, Dong L, Bai J, Wang D Front Microbiol. 2022; 13:980615.

PMID: 36016791 PMC: 9395700. DOI: 10.3389/fmicb.2022.980615.


Epigenetic Regulation of Antifungal Drug Resistance.

Patra S, Raney M, Pareek A, Kaur R J Fungi (Basel). 2022; 8(8).

PMID: 36012862 PMC: 9409733. DOI: 10.3390/jof8080875.


References
1.
Whitesell L, Lindquist S . HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005; 5(10):761-72. DOI: 10.1038/nrc1716. View

2.
Howard S, Cerar D, Anderson M, Albarrag A, Fisher M, Pasqualotto A . Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009; 15(7):1068-76. PMC: 2744247. DOI: 10.3201/eid1507.090043. View

3.
Kaliszczak M, Trousil S, Aberg O, Perumal M, Nguyen Q, Aboagye E . A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth. Br J Cancer. 2013; 108(2):342-50. PMC: 3566806. DOI: 10.1038/bjc.2012.576. View

4.
Tribus M, Galehr J, Trojer P, Brosch G, Loidl P, Marx F . HdaA, a major class 2 histone deacetylase of Aspergillus nidulans, affects growth under conditions of oxidative stress. Eukaryot Cell. 2005; 4(10):1736-45. PMC: 1265891. DOI: 10.1128/EC.4.10.1736-1745.2005. View

5.
Sanderson L, Taylor G, Aboagye E, Alao J, Latigo J, Coombes R . Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice. Drug Metab Dispos. 2004; 32(10):1132-8. DOI: 10.1124/dmd.104.000638. View